These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


PUBMED FOR HANDHELDS

Journal Abstract Search


241 related items for PubMed ID: 7607342

  • 21. Inhibitory effects of Ganoderma applanatum on rat lens aldose reductase and sorbitol accumulation in streptozotocin-induced diabetic rat tissues.
    Jung SH, Lee YS, Shim SH, Lee S, Shin KH, Kim JS, Kim YS, Kang SS.
    Phytother Res; 2005 Jun; 19(6):477-80. PubMed ID: 16114079
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Raman spectroscopic study of the effect of aldose reductase inhibitor on experimental diabetic cataract.
    Nozawa H, Yaginuma T, Mizuno A.
    Nippon Ganka Gakkai Zasshi; 1988 Jan; 92(1):194-201. PubMed ID: 3133929
    [No Abstract] [Full Text] [Related]

  • 26. Aldose reductase inhibitor fidarestat attenuates leukocyte-endothelial interactions in experimental diabetic rat retina in vivo.
    Hattori T, Matsubara A, Taniguchi K, Ogura Y.
    Curr Eye Res; 2010 Feb; 35(2):146-54. PubMed ID: 20136425
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Focus on molecules: aldose reductase.
    Anil Kumar P, Bhanuprakash Reddy G.
    Exp Eye Res; 2007 Dec; 85(6):739-40. PubMed ID: 16997295
    [No Abstract] [Full Text] [Related]

  • 29. [Role of aldose reductase inhibitors in the development of peripheral neuropathy in experimental diabetes].
    Kuchmerovskaia TM, Donchenko GV, Klimenko AP, Chichkovskaia GV, Pakirbaeva LV, Kozitskiĭ ZIa, Efimov AS.
    Ukr Biokhim Zh (1978); 1997 Dec; 69(3):77-82. PubMed ID: 9505366
    [Abstract] [Full Text] [Related]

  • 30. Aldose reductase inhibitors.
    Kirchain WR, Rendell MS.
    Pharmacotherapy; 1990 Dec; 10(5):326-36. PubMed ID: 2122421
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Prevention of experimental diabetic corneal endotheliopathy with aldose reductase inhibitor].
    Akagi Y, Takahashi Y, Tanabe T, Ikebe H, Majima K, Miyatani H, Miyamoto Y, Terubayashi H.
    Nippon Ganka Gakkai Zasshi; 1987 Feb; 91(2):187-93. PubMed ID: 3111199
    [No Abstract] [Full Text] [Related]

  • 34. Aldose reductase inhibitors and diabetic complications.
    Tomlinson DR, Willars GB, Carrington AL.
    Pharmacol Ther; 1992 Feb; 54(2):151-94. PubMed ID: 1438531
    [Abstract] [Full Text] [Related]

  • 35. Aldose reductase in diabetic complications of the eye.
    Kinoshita JH, Fukushi S, Kador P, Merola LO.
    Metabolism; 1979 Apr; 28(4 Suppl 1):462-9. PubMed ID: 45423
    [Abstract] [Full Text] [Related]

  • 36. Aldose reductase inhibitors and cataract.
    Crabbe MJ.
    Int Ophthalmol; 1991 Jan; 15(1):25-36. PubMed ID: 1901300
    [Abstract] [Full Text] [Related]

  • 37. Aldose reductase inhibitors as pathobiochemical probes.
    Dvornik D.
    J Diabetes Complications; 1992 Jan; 6(1):25-34. PubMed ID: 1562755
    [Abstract] [Full Text] [Related]

  • 38. Aldose reductase expression as a risk factor for cataract.
    Snow A, Shieh B, Chang KC, Pal A, Lenhart P, Ammar D, Ruzycki P, Palla S, Reddy GB, Petrash JM.
    Chem Biol Interact; 2015 Jun 05; 234():247-53. PubMed ID: 25541468
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Aldose reductase inhibitor fidarestat counteracts diabetes-associated cataract formation, retinal oxidative-nitrosative stress, glial activation, and apoptosis.
    Drel VR, Pacher P, Ali TK, Shin J, Julius U, El-Remessy AB, Obrosova IG.
    Int J Mol Med; 2008 Jun 05; 21(6):667-76. PubMed ID: 18506358
    [Abstract] [Full Text] [Related]


    Page: [Previous] [Next] [New Search]
    of 13.